

Second Regular Session
Seventy-third General Assembly
STATE OF COLORADO

REVISED

*This Version Includes All Amendments Adopted
on Second Reading in the Second House*

LLS NO. 22-0590.01 Jane Ritter x4342

HOUSE BILL 22-1344

HOUSE SPONSORSHIP

Neville and Ortiz, Bennett, Boesenecker, Cutter, Esgar, Exum, Gray, Herod, Hooton, Kennedy, Lindsay, Michaelson Jenet, Sirota, Titone, Valdez A., Woodrow, Young

SENATE SPONSORSHIP

Cooke and Ginal,

House Committees

Public & Behavioral Health & Human Services

Senate Committees

Health & Human Services

A BILL FOR AN ACT

101 CONCERNING THE LAWFUL USE OF A PRESCRIPTION DRUG THAT
102 CONTAINS **3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA)**
103 THAT IS APPROVED BY THE UNITED STATES FOOD AND DRUG
104 ADMINISTRATION.

Bill Summary

(Note: This summary applies to this bill as introduced and does not reflect any amendments that may be subsequently adopted. If this bill passes third reading in the house of introduction, a bill summary that applies to the reengrossed version of this bill will be available at <http://leg.colorado.gov>.)

The bill states that if the United States food and drug administration approves a prescription medicine that contains 3,4-methylenedioxyamphetamine (MDMA), and if that medicine has

Shading denotes HOUSE amendment. Double underlining denotes SENATE amendment.
Capital letters or bold & italic numbers indicate new material to be added to existing statute.
Dashes through the words indicate deletions from existing statute.

SENATE
2nd Reading Unamended
April 28, 2022

HOUSE
3rd Reading Unamended
April 8, 2022

HOUSE
Amended 2nd Reading
April 7, 2022

been placed on a schedule of the federal "Controlled Substances Act", other than schedule I, or has been exempted from one or more provisions of such act, then thereafter prescribing, dispensing, transporting, possessing, and using that prescription drug is legal in Colorado.

1 *Be it enacted by the General Assembly of the State of Colorado:*

2 **SECTION 1. Legislative declaration.** (1) The general assembly
3 finds and declares that:

4 (a) The effects of post-traumatic stress disorder (PTSD) in
5 patients, along with common comorbidities such as, but not limited to,
6 disassociation, depression, and childhood trauma, represent a major
7 public health crisis for which the currently available treatments are
8 described by medical experts as modest at best;

9 (b) Veterans, first responders, survivors of sexual assault,
10 survivors of natural disasters, and other vulnerable populations who have
11 experienced or witnessed a life-threatening or traumatic event are
12 disproportionately likely to suffer from PTSD and common
13 comorbidities;

14 (c) According to the national center for PTSD, six percent of the
15 population of the United States will have PTSD at some point in their
16 lives and, in any given year, about fifteen million adults have PTSD;

17 (d) The federal department of veterans affairs spent seventeen
18 billion dollars on disability payments for more than one million veterans
19 with PTSD;

20 (e) Results from a phase 3 clinical trial in 2021 demonstrated that
21 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the
22 treatment of patients with severe PTSD and other comorbidities can be
23 highly effective if paired with talk therapy and counseling. In that clinical

1 trial, two out of three study participants were no longer considered to
2 have a PTSD diagnosis after treatment and eighty-eight percent
3 experienced a clinically significant reduction in symptoms.

4 (f) In 2015, the United States congress passed the "Improving
5 Regulatory Transparency for New Medical Therapies Act", which gives
6 the federal drug enforcement administration ninety days to schedule a
7 substance under the federal "Controlled Substances Act" when it is
8 approved for use by the federal food and drug administration; and

9 (g) As of March 2022, it is widely expected that the federal food
10 and drug administration will approve MDMA-assisted therapy for
11 prescription use for PTSD as soon as 2023.

12 (2) Therefore, the general assembly declares that it is in the best
13 interests of the people of Colorado that behavioral health professionals in
14 Colorado have the ability to provide MDMA-assisted therapy to treat
15 patients with PTSD and other comorbidities if the federal food and drug
16 administration ultimately approves it for prescription use.

17 **SECTION 2.** In Colorado Revised Statutes, 18-18-203, **amend**
18 (2)(c)(VII) as follows:

19 **18-18-203. Schedule I.** (2) Unless specifically excepted by
20 Colorado or federal law or Colorado or federal regulation or more
21 specifically included in another schedule, the following controlled
22 substances are listed in schedule I:

23 (c) Any material, compound, mixture, or preparation containing
24 any quantity of the following hallucinogenic substances, including any
25 salts, isomers, and salts of isomers of them that are theoretically possible
26 within the specific chemical designation:

27 (VII) 3,4-methylenedioxymethamphetamine (MDMA); EXCEPT

1 THAT 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) DOES NOT
2 INCLUDE A PRESCRIPTION DRUG PRODUCT CONTAINING
3 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) APPROVED BY THE
4 FEDERAL FOOD AND DRUG ADMINISTRATION AND PLACED ON A SCHEDULE
5 OF THE FEDERAL "CONTROLLED SUBSTANCES ACT", 21 U.S.C. SEC. 801 ET
6 SEQ., AS AMENDED, OTHER THAN SCHEDULE I, OR HAS BEEN EXEMPTED
7 FROM ONE OR MORE PROVISIONS OF SUCH ACT, AND THAT IS INTENDED FOR
8 PRESCRIBED USE AND DISPENSED BY A PHARMACY OR PRESCRIPTION DRUG
9 OUTLET REGISTERED BY THE STATE OF COLORADO AND ONLY POSSESSED
10 BY A PERSON AUTHORIZED TO POSSESS A CONTROLLED SUBSTANCE
11 PURSUANT TO SECTION 18-18-302. ANY SUCH DRUG PRODUCT CONTAINING
12 MDMA THAT IS APPROVED BY THE FEDERAL FOOD AND DRUG
13 ADMINISTRATION MUST BE CONTROLLED IN COLORADO IN THE SAME
14 MANNER AS REQUIRED BY ANY FEDERAL CONTROL DESIGNATION
15 PURSUANT TO THE FEDERAL "CONTROLLED SUBSTANCES ACT", OR ANY
16 EXEMPTION FROM ONE OR MORE PROVISIONS OF THAT ACT, AND SUBJECT
17 TO THE PROVISIONS SET FORTH IN PART 1 OF ARTICLE 280 OF TITLE 12 AND
18 PART 3 OF THIS ARTICLE 18. NOTHING IN THIS SECTION EXEMPTS A PERSON
19 FROM ANY VIOLATION OF PART 4 OF THIS ARTICLE 18.

20 **SECTION 3. Act subject to petition - effective date.** This act
21 takes effect at 12:01 a.m. on the day following the expiration of the
22 ninety-day period after final adjournment of the general assembly; except
23 that, if a referendum petition is filed pursuant to section 1 (3) of article V
24 of the state constitution against this act or an item, section, or part of this
25 act within such period, then the act, item, section, or part will not take
26 effect unless approved by the people at the general election to be held in

- 1 November 2022 and, in such case, will take effect on the date of the
- 2 official declaration of the vote thereon by the governor.